# Telcagepant (MK-0974) Treatment of Migraine in Participants With Stable Vascular Disease (MK-0974-034)

> **NCT00662818** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 165 (actual)

## Conditions studied

- Migraine Disorders
- Heart Disease
- Cerebrovascular Accident
- TIA (Transient Ischemic Attack)
- Vascular Diseases
- Peripheral Vascular Diseases

## Interventions

- **DRUG:** Telcagepant
- **DRUG:** Acetaminophen/Paracetamol
- **DRUG:** Placebo to Telcagepant
- **DRUG:** Placebo to Acetaminophen/Paracetamol

## Key facts

- **NCT ID:** NCT00662818
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03-17
- **Primary completion:** 2009-09-02
- **Final completion:** 2009-09-02
- **Target enrollment:** 165 (ACTUAL)
- **Last updated:** 2018-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00662818

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00662818, "Telcagepant (MK-0974) Treatment of Migraine in Participants With Stable Vascular Disease (MK-0974-034)". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT00662818. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*